Breathe Well Live Well
|
Surveyed Pulmonologists and Payers Anticipate More Controls on Branded …
The Providence Journal BURLINGTON, Mass., March 5, 2014 /PRNewswire/ — Decision Resources Group finds that as the Affordable Care Act drives up the demand for asthma drugs, exchange-based plans will impose more cost controls and prescribing barriers than commercial … |
View full post on asthma – Google News
|
Surveyed Pulmonologists and Payers Anticipate More Controls on Branded …
PR Newswire (press release) BURLINGTON, Mass., March 5, 2014 /PRNewswire/ — Decision Resources Group finds that as the Affordable Care Act drives up the demand for asthma drugs, exchange-based plans will impose more cost controls and prescribing barriers than commercial … |
View full post on asthma – Google News
|
For Persistent Asthma, Surveyed Pulmonologists Indicate That a Reduced Rate …
PR Newswire (press release) The DecisionBase report entitled Asthma: Where do Pulmonologists and Payers Signal the Greatest Need—and Greatest Opportunity for Differentiation—for Novel Therapies for Persistent Disease? finds that surveyed U.S. and European pulmonologists and … |
View full post on asthma – Google News
|
US pulmonologists view refractory asthma patient treatment with biosimilar …
The Pharma Letter US pulmonologists surveyed by health care advisory firm Decision Resources estimate that only 19% percent of their severe, refractory asthma patients are treated with Genentech and Novartis' Xolair (omalizumab), the only approved drug that serves this … |
View full post on asthma – Google News